- Novo Nordisk will lower semaglutide prices starting in 2026.
- Medicare Part D will cover anti-obesity medicines via a pilot program.
- Novo Nordisk expects a low single-digit negative impact on 2026 global sales growth.
- Details of the agreement with the U.S. Administration are being finalized.
Agreement Overview
Novo Nordisk has reached an agreement with the U.S. Administration to lower the prices of its semaglutide medicines, including Wegovy® and Ozempic®, starting in 2026. This initiative aims to expand patient access and affordability in U.S. Medicare Part D, Medicaid, and direct-to-patient cash channels.
Medicare Part D Pilot Program
A pilot program will be introduced to provide Medicare Part D coverage for anti-obesity medicines, targeting a majority of Part D beneficiaries. This move is expected to enhance access to obesity treatments for eligible patients.
Financial Impact
Novo Nordisk anticipates a low single-digit negative impact on its global sales growth in 2026 due to the price reductions. The company will provide a financial outlook for 2026 in conjunction with its full-year 2025 results announcement.
Next Steps
The details of the agreement with the U.S. Administration are currently being finalized. Novo Nordisk is also expected to receive a three-year tariff exemption as part of this arrangement.
